This horizontal bar chart displays hospital beds (per 1,000 people) by ISO 3 country code using the aggregation average, weighted by population in Netherlands. The data is about countries per year.

In 2023, there were nearly 11 thousand hospitals in Columbia, the highest number among OECD countries, followed by 8,156 hospitals in Japan. If only general hospitals were counted (excluding mental health hospitals and other specialized hospitals), Japan had the most number of general hospitals among OECD countries worldwide. Most countries reported hospitals numbers similar to or lower than the previous year. Meanwhile, Mexico, South Korea and the Netherlands all reported more hospitals than last year.

The Netherlands diagnostic imaging equipment market, valued at €597.10 million in 2025, is projected to experience steady growth, driven by a rising elderly population, increasing prevalence of chronic diseases like cardiovascular conditions and cancer, and advancements in imaging technologies offering improved diagnostic accuracy and faster scan times. The market's 4.21% CAGR from 2019-2024 indicates a consistent demand for sophisticated imaging equipment. Key growth segments include high-field MRI systems, high-end CT scanners, and advanced ultrasound systems, reflecting a preference for superior image quality and detailed diagnostic information. Hospitals and diagnostic centers constitute the dominant end-users, accounting for a significant portion of market revenue. Technological advancements, like AI-powered image analysis and cloud-based image management systems, are further boosting market expansion. However, high equipment costs, stringent regulatory approvals, and the need for skilled professionals to operate and interpret images are potential restraints. Competitive intensity is high, with major players like Philips, Siemens Healthineers, and GE Healthcare vying for market share through technological innovations and strategic partnerships. The market is expected to continue its upward trajectory throughout the forecast period (2025-2033), fueled by increased healthcare spending and government initiatives aimed at improving healthcare infrastructure and patient outcomes. While precise regional breakdowns within the Netherlands aren't provided, extrapolating from similar European markets suggests a concentration of equipment purchases in major urban centers with a high density of hospitals and specialized clinics. The forecast for the Netherlands diagnostic imaging market from 2025-2033 is optimistic, anticipating consistent year-on-year growth based on the historical CAGR. This growth reflects not just an increase in the volume of procedures but also the progressive adoption of newer, more sophisticated technologies. Continued investment in research and development by leading manufacturers is expected to drive innovation, creating new opportunities for market expansion. Furthermore, the increasing integration of imaging equipment with hospital information systems (HIS) and picture archiving and communication systems (PACS) streamlines workflows and enhances data management, which fosters increased adoption. While competitive pressures remain strong, the overall market outlook is positive, suggesting substantial growth prospects for established players and potentially new entrants in the coming years. Recent developments include: October 2023: Royal Philips, a health technology company based in the Netherlands, introduced its Philips CT 3500. This state-of-the-art CT system is designed to address the demands of routine radiology and high-volume screening programs. By leveraging AI-powered workflow enhancements and advanced image reconstruction capabilities, the Philips CT 3500 ensures increased productivity and first-time-right imaging, thereby improving the speed and accuracy of diagnoses.August 2023: GE HealthCare launched the Vscan Air SL handheld ultrasound device at the European Society of Cardiology (ESC) Congress in Amsterdam, Netherlands. This FDA-cleared device features sector and linear arrays, allowing for seamless cardiac and vascular assessments at the point of care.. Key drivers for this market are: Rise in the Prevalence of Chronic Diseases, Technological Advancement in Imaging Modalities; Increasing Geriatric Population. Potential restraints include: Rise in the Prevalence of Chronic Diseases, Technological Advancement in Imaging Modalities; Increasing Geriatric Population. Notable trends are: The Oncology Segment is Expected to Witness Growth During the Forecast Period.

The global healthcare RFID market, valued at approximately $X million in 2025, is projected to experience steady growth, driven by increasing demand for efficient patient and asset tracking, improved medication management, and enhanced supply chain visibility within healthcare settings. A Compound Annual Growth Rate (CAGR) of 2.45% indicates a consistent expansion throughout the forecast period (2025-2033). Key drivers include the rising prevalence of chronic diseases necessitating advanced monitoring, stringent regulatory compliance requirements for drug traceability, and the growing adoption of electronic health records (EHRs) systems that integrate seamlessly with RFID technology. Technological advancements, such as the development of smaller, more cost-effective RFID tags and improved reader sensitivity, are further fueling market growth. Segmentation analysis reveals a significant contribution from RFID systems, particularly asset and patient tracking, within hospitals and pharmaceutical companies. While the market faces restraints such as the initial high investment costs associated with RFID implementation and concerns regarding data security and privacy, the long-term benefits in terms of improved efficiency, reduced errors, and enhanced patient safety are expected to outweigh these challenges. The North American market currently holds a dominant share, attributable to advanced healthcare infrastructure and early adoption of innovative technologies; however, the Asia Pacific region is anticipated to showcase significant growth potential driven by expanding healthcare infrastructure and increasing government initiatives. The competitive landscape is characterized by a mix of established players like Zebra Technologies, Avery Dennison, and Honeywell, alongside specialized RFID solution providers. These companies are continuously striving for innovation through product diversification, strategic partnerships, and mergers and acquisitions to solidify their market position. Future growth will depend on factors such as the development of interoperable RFID systems, integration with existing healthcare IT infrastructure, and the ability to address evolving data privacy regulations. The market's trajectory suggests that RFID technology will play a progressively critical role in modernizing healthcare operations and improving overall patient care. Specific growth within segments will likely be influenced by the successful integration of RFID into existing healthcare workflows, resulting in demonstrable improvements in efficiency and cost savings. Recent developments include: February 2023: The Dutch VieCuri Medical Center is expanding its collaboration with Ascom with a framework agreement to deploy a state-of-the-art nursing and medical call system. This solution provides reliable primary care alarms throughout the hospital. It involves patient alerting and integrated medical equipment at the bedside. As a top clinical hospital, VieCuri Medical Center has several Netherlands locations with over 3000 employees., October 2022: Biolog-id announced the RFID kit, specially designed for businesses dealing with many Red Blood Cells, has been released. After successful market validation, the new HD kit has been used at several client locations. It confirms that this solution can support the best inventory management in a highly challenging and complex environment.. Key drivers for this market are: Growing Stringency in the Pharmaceutical Sector with Regards to Medicine Labeling, Increased Applications and Use of Devices Supporting RFID Across the Healthcare Sector. Potential restraints include: Growing Stringency in the Pharmaceutical Sector with Regards to Medicine Labeling, Increased Applications and Use of Devices Supporting RFID Across the Healthcare Sector. Notable trends are: Pharmaceuticals to Witness the Growth.

In 2022, the national healthcare expenditure reached a value of more than 107.6 billion euros, nearly equaling the amount spent in the previous year. In a population of over 17 million people, this came to around 7,116 euros worth of Dutch health care expenses per capita. This figure was higher than those of other European countries. The per capita health expenditure of Italy, for example, stood at slightly over 2,800 euros in 2021, less than half that of the Netherlands. There are some who say, however, that this difference in health costs stems from how Dutch health insurance works.

Dutch health insurance: one for all, all for one

The Dutch health system combines private market elements with government supervision to make health care cost-efficient. Simply put, the Dutch government decides which care is covered by the mandatory “basic” health insurance. This can change every year and be influenced by politics. Therefore, health care in the Netherlands is accessible to (and paid for by) everybody, whether one uses it or not. This system is funded in three ways. First, there is a nominal annual premium of more than 1,500 euros (or 125 euros per month) that everybody pays, regardless of age or job situation. Second, some employers pay health care costs, depending on certain industries. Third, there is what is called eigen risico or “own risk”/”excess”. This lump sum is compulsory from the age of 18 to pay before the basic health insurance starts reimbursing medical costs. In 2021, the value of this “verplichte eigen risico” was 385 euros. This is without counting the price a health insurance company might charge.

Dutch health care: getting what one pays for

The government decides the contents of the national health insurance package. Quality and pricing, however, are left to the health providers and health insurers. This is the other idea behind health care in the Netherlands: it should be accessible to all, but the free market is responsible for assuring quality and low costs. Dutch health care ranked as some of the best found in Europe, and the Dutch used it relatively often as can be seen in an overview of doctor visits in different European countries.

Snapshot img

Hospital Furniture Market Size 2024-2028

The hospital furniture market size is forecast to increase by USD 8 billion, at a CAGR of 8.06% between 2023 and 2028.

The market is experiencing significant growth due to the increasing international accreditation of hospitals. This trend is driven by the increasing emphasis on providing high-quality patient care and facilities that meet international standards. However, this market also faces challenges, primarily from the growing geriatric population and the limited sustainability of smaller companies. The geriatric population's increasing need for specialized furniture and medical equipment is putting pressure on hospitals to invest in more comfortable and accessible solutions. Meanwhile, The market's competitive landscape is fragmented, with numerous small companies struggling to remain profitable. These companies face challenges in meeting the demand for high-quality, cost-effective solutions while also competing with larger, more established players.
Companies seeking to capitalize on market opportunities must focus on innovation, sustainability, and cost-effectiveness to differentiate themselves and meet the evolving needs of hospitals and their patients. Additionally, collaborations and partnerships with healthcare providers and industry associations can help smaller companies gain market share and build a strong brand presence. Overall, the market presents both opportunities and challenges, requiring strategic planning and a focus on meeting the unique needs of healthcare providers and their patients.

What will be the Size of the Hospital Furniture Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2018-2022 and forecasts 2024-2028 - in the full report.
Request Free Sample

The market continues to evolve, with dynamic market activities shaping its landscape. HVAC systems are integrated into hospital designs to ensure optimal indoor air quality, enhancing patient and staff comfort. Work flow optimization and supply chain management are crucial for efficient operations, while infection prevention remains a top priority. Medical cabinets and medical carts facilitate easy access to essential medical equipment, and hospital beds and operating tables are designed for patient comfort and safety. Space planning is essential for maximizing efficiency in healthcare facilities, with sterilization equipment and infection control measures integrated into the design.

Steel furniture offers durability and strength, while anesthesia machines and biomedical engineering solutions enable advanced medical procedures. Patient handling equipment, including patient lifts and overbed tables, ensures safe patient transfer and positioning. Customizable furniture caters to the unique needs of various sectors, such as nursing homes and rehabilitation centers. Antimicrobial coatings and material science advancements contribute to hygiene standards, while fire safety and weight capacity are critical considerations. Staff training and regulatory compliance are ongoing priorities, ensuring the effective use of all furniture and equipment. Modular furniture offers flexibility in design and layout, while iv poles and storage cabinets cater to the diverse needs of healthcare facilities.

Electrical systems and medical imaging systems are integrated into the furniture design for seamless functionality. Patient comfort and patient monitors are essential for positive patient experiences, with patient lifts and nursing home furniture designed to cater to the specific needs of elderly patients. The market is characterized by continuous innovation and adaptation to meet the evolving needs of healthcare facilities and patients. From HVAC systems to medical imaging systems, every aspect of hospital furniture is designed with patient safety, staff efficiency, and infection prevention in mind. The ongoing integration of technology and material science advancements ensures that hospital furniture remains a vital component of modern healthcare facilities.

How is this Hospital Furniture Industry segmented?

The hospital furniture industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Application

  Physician furniture
  Patient furniture
  Staff furniture


Product

  Hospital beds
  Specialty medical chairs and tables
  Others


Geography

  North America

    US
    Canada


  Europe

    Germany
    UK


  APAC

    China


  Rest of World (ROW)

By Application Insights

The physician furniture segment is estimated to witness significant growth during the forecast period.

The healthcare sector's evolution has led to an increased focus on creating advanced and comforta

BackgroundAcute gastroenteritis is a highly contagious disease demanding effective public health and clinical care systems for prevention and early intervention to avoid outbreaks and symptom deterioration. The Netherlands and Australia are both top-performing, high-income countries where general practitioners (GPs) act as healthcare gatekeepers. However, there is a lower annual incidence and per-case costs for childhood gastroenteritis in Australia. Understanding the systems and policies in different countries can lead to improvements in processes and care. Therefore, we aimed to compare public health systems and clinical care for children with acute gastroenteritis in both countries.MethodsA cross-country expert study was conducted for the Netherlands and Australia. Using the Health System Performance Assessment framework and discussions within the research group, two questionnaires (public health and clinical care) were developed. Questionnaires were delivered to local experts in the Netherlands and the state of Victoria, Australia. Data synthesis employed a narrative approach with constant comparison.ResultsIn Australia, rotavirus vaccination is implemented in a national program with immunisation requirements and legislation for prevention, which is not the case in the Netherlands. Access to care differs, as Dutch children must visit their regular GP before the hospital, while in Australia, children have multiple options and can go directly to hospital. Funding varies, with the Netherlands providing fully funded healthcare for children, whilst in Australia it depends on which GP (co-payment required or not) and hospital (public or private) they visit. Additionally, the guideline-recommended dosage of the antiemetic ondansetron is lower in the Netherlands.ConclusionsHealthcare approaches for managing childhood gastroenteritis differ between the Netherlands and Australia. The lower annual incidence and per-case costs for childhood gastroenteritis in Australia cannot solely be explained by the differences in healthcare system functions. Nevertheless, Australia’s robust public health system, characterized by legislation for vaccinations and quarantine, and the Netherland’s well-established clinical care system, featuring fully funded continuity of care and lower ondansetron dosages, offer opportunities for enhancing healthcare in both countries.

BackgroundAcute gastroenteritis is a highly contagious disease demanding effective public health and clinical care systems for prevention and early intervention to avoid outbreaks and symptom deterioration. The Netherlands and Australia are both top-performing, high-income countries where general practitioners (GPs) act as healthcare gatekeepers. However, there is a lower annual incidence and per-case costs for childhood gastroenteritis in Australia. Understanding the systems and policies in different countries can lead to improvements in processes and care. Therefore, we aimed to compare public health systems and clinical care for children with acute gastroenteritis in both countries.MethodsA cross-country expert study was conducted for the Netherlands and Australia. Using the Health System Performance Assessment framework and discussions within the research group, two questionnaires (public health and clinical care) were developed. Questionnaires were delivered to local experts in the Netherlands and the state of Victoria, Australia. Data synthesis employed a narrative approach with constant comparison.ResultsIn Australia, rotavirus vaccination is implemented in a national program with immunisation requirements and legislation for prevention, which is not the case in the Netherlands. Access to care differs, as Dutch children must visit their regular GP before the hospital, while in Australia, children have multiple options and can go directly to hospital. Funding varies, with the Netherlands providing fully funded healthcare for children, whilst in Australia it depends on which GP (co-payment required or not) and hospital (public or private) they visit. Additionally, the guideline-recommended dosage of the antiemetic ondansetron is lower in the Netherlands.ConclusionsHealthcare approaches for managing childhood gastroenteritis differ between the Netherlands and Australia. The lower annual incidence and per-case costs for childhood gastroenteritis in Australia cannot solely be explained by the differences in healthcare system functions. Nevertheless, Australia’s robust public health system, characterized by legislation for vaccinations and quarantine, and the Netherland’s well-established clinical care system, featuring fully funded continuity of care and lower ondansetron dosages, offer opportunities for enhancing healthcare in both countries.

This table presents a wide variety of historical data in the field of health, lifestyle and health care. Figures on births and mortality, causes of death and the occurrence of certain infectious diseases are available from 1900, other series from later dates. In addition to self-perceived health, the table contains figures on infectious diseases, hospitalisations per diagnosis, life expectancy, lifestyle factors such as smoking, alcohol consumption and obesity, and causes of death. The table also gives information on several aspects of health care, such as the number of practising professionals, the number of available hospital beds, nursing day averages and the expenditures on care. Many subjects are also covered in more detail by data in other tables, although sometimes with a shorter history. Data on notifiable infectious diseases and HIV/AIDS are not included in other tables.

Data available from: 1900

Status of the figures:

2025: The available figures are definite.

2024: Most available figures are definite. Figures are provisional for: - notifiable infectious diseases, hiv, aids; - causes of death.

2023: Most available figures are definite. Figures are provisional for: - notifiable infectious diseases, HIV/AIDS; - diagnoses at hospital admissions; - number of hospital discharges and length of stay; - number of hospital beds; - health professions; - perinatal and infant mortality. Figures are revised provisional for: - expenditures on health and welfare.

2022: Most available figures are definite. Figures are provisional for: - notifiable infectious diseases, HIV/AIDS; - diagnoses at hospital admissions; - number of hospital discharges and length of stay; - number of hospital beds; - health professions. Figures are revised provisional for: - expenditures on health and welfare.

2021: Most available figures are definite. Figures are provisional for: - notifiable infectious diseases, HIV/AIDS; Figures are revised provisional for: - expenditures on health and welfare.

2020 and earlier: Most available figures are definite. Due to 'dynamic' registrations, figures for notifiable infectious diseases, HIV/AIDS remain provisional.

Changes as of 4 July 2025: The most recent available figures have been added for: - population on January 1; - live born children, deaths; - persons in (very) good health; - notifiable infectious diseases, HIV/AIDS; - diagnoses at hospital admissions; - use of medication; - sickness absence; - lifestyle; - use of health care services; - number of hospital discharges and length of stay; - number of hospital beds; - health professions; - expenditures on health and welfare; - healthy life expectancy; - causes of death.

Changes as of 18 december 2024: - Due to a revision of the statistics Health and welfare expenditure 2021, figures for expenditure on health and welfare have been replaced from 2021 onwards. - Revised figures on the volume index of healthcare costs are not yet available, these figures have been deleted from 2021 onwards.

When will new figures be published? December 2025.

Model input parameters and value ranges for sensitivity analyses.

Additional file 1: Table S1. Metadata table related to the 309 vanA-type vancomycin-resistant Enterococcus faecium isolates. (CSV 20 kb)

The size of the Healthcare 3D Printers Industry in Europe market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 15.40% during the forecast period. The healthcare 3D printer's industry has grown rapidly in Europe, based on increased technological advancements in 3D printing and the need for patient-specific treatments in healthcare. Currently used in nearly all applications, including prosthetics, implants, surgical planning, and even bioprinting, 3D printing or additive manufacturing is fast becoming ubiquitous in healthcare. It can offer very specialized medical equipment, models, and devices but is more accurate and cost-effective than regular ones. The European healthcare market for 3D printing receives considerable support also due to the government, funding, and communication between hospitals/clinics and technology companies. The leading countries on this are Germany, the UK, and the Netherlands, where most of their hospitals and research institutes have begun adopting 3D printing as part of their operations. The application of 3D printing by surgeons enables them to prepare complicated cases that can produce very accurate anatomical models. This has yielded various benefits since the more accurate surgeries result in reduced hours taken in operations. At the same time, with the production of individual prostheses and implants like custom knee joints or dental implants, this may be good for better results and comfort for patients. Recent developments include: July 2022: Sculpteo and Daniel Robert Orthopedic launched a Bio-sourced 3D printed device. The collaboration will produce orthopedic devices from a bio-sourced material that will be made possible by 3D printing., June 2021: Stratasys launched the J5 MediJet Medical 3D printer, which enables users to create highly detailed 3D anatomical models and drilling and cutting guides with approved third-party 510k-cleared segmentation software.. Key drivers for this market are: Technological Advancements Leading to Enhanced Application, Increasing Demand for Customized 3D Printing. Potential restraints include: Lack of Trained Professionals, Absence of Specific Regulatory Guidelines. Notable trends are: Metal and Alloy Segment is Dominating the European Healthcare 3D Printing Market Over the Forecast Period.

オランダの1,000人当たりの病院の病床数の統計データです。最新の2018年の数値「3.17(数/1,000人)」を含む1990～2018年までの推移表や他国との比較情報を無料で公開しています。csv形式でのダウンロードも可能でEXCELでも開けますので、研究や分析レポートにお役立て下さい。

The global market for fat metaboliser tablets is experiencing robust growth, projected to reach a value of $1060.6 million in 2025 and maintain a Compound Annual Growth Rate (CAGR) of 24.1% from 2025 to 2033. This significant expansion is driven by several factors. Increasing awareness of obesity and related health risks, coupled with a growing preference for convenient weight management solutions, is fueling consumer demand. The market is also witnessing innovation in formulation and ingredient technology, with an increasing focus on natural and clinically-proven ingredients like green tea extract, L-Carnitine, and Ursolic Acid, enhancing efficacy and appeal. The rise of online retail channels is further boosting accessibility and market reach. However, potential restraints include concerns about the efficacy and safety of some fat metaboliser products, along with regulatory hurdles and potential side effects associated with certain ingredients. The market segmentation reveals a strong presence across various sales channels, including hospitals, health product stores, and online retailers, catering to diverse consumer preferences and access points. The leading companies, including Holland & Barrett, Metrx, Protein World, Lean Active, and Amcal, are leveraging strategic marketing and product diversification to capture market share. Geographic analysis shows strong growth potential across North America and Europe, driven by high consumer awareness and disposable incomes. The Asia-Pacific region is also expected to contribute significantly, fueled by rising health consciousness and increasing adoption of Western lifestyle patterns. The continued growth of the fat metaboliser tablet market is strongly tied to the evolving consumer landscape. Consumers are actively seeking effective and convenient methods for weight management, aligning perfectly with the convenience and accessibility offered by these supplements. The market's success hinges on addressing concerns regarding product safety and efficacy through rigorous research and development, transparency in ingredient sourcing and labeling, and increased consumer education on responsible supplement use. Furthermore, manufacturers can leverage personalized approaches to improve product relevance and tailor marketing strategies to specific demographics and needs. This will be pivotal in sustaining the high CAGR and expanding the market’s reach further.

Among all countries that are part of the Organization for Economic Co-operation and Development (OECD), Turkey, followed by Korea, had the highest rate of Caesarean section births (or C-sections) in 2022. At that time, the rate of C-sections in Turkey was roughly 600 per 1,000 live births. Among global regions, Latin America and the Caribbean had the highest percentage of births that were delivered by C-section, while sub-Saharan Africa had the lowest rates of Cesarean section births. Cesarean section costs A Cesarean section is a form of birth where the baby is taken out through a surgical incision in the abdomen rather than a natural vaginal birth. The cost of a Cesarean section delivery varies globally, with the United States having the highest cost globally for Cesarean section deliveries, while Germany the lowest cost among selected countries worldwide. In the United States, C-sections are significantly more expensive than a delivery by vaginal birth. High C-sections rates in the U.S. Over the past 20 years the C-section rate in the U.S. has gradually been increasing with more stable trends in the past few years. It has been reported that many of the C-sections performed in the U.S. are elective and not necessary. Often, the risks of C-sections are greater than the benefits, when performed as an elective procedure. Therefore, the United States has a "healthy people target" for the c-section rate of first time, low-risk mothers. However, less than half of hospitals are meeting the national targets for Cesarean sections performed.